Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors

Journal of Medicinal Chemistry
2015.0

Abstract

The V600E missense mutation in B-Raf kinase leads to an anomalous regulation of the MAPK pathway, uncontrolled cell proliferation, and initiation of tumorigenesis. While the ATP-competitive B-Raf inhibitors block the MAPK pathway in B-Raf mutant cells, they induce conformational changes to wild-type B-Raf kinase domain leading to heterodimerization with C-Raf causing a paradoxical hyperactivation of MAPK pathway. A new class of inhibitors (paradox breakers) has been developed that inhibit B-Raf(V600E) activity without agonistically affecting the MAPK pathway in wild-type B-Raf cells. In this study, we explore the structural, conformational, and cellular effects on the B-Raf kinase domain upon binding of paradox breakers and inducers. Our results indicate that a subtle structural difference between paradox inducers and breakers leads to significant conformational differences when complexed with B-Raf. This study provides a novel insight into the activation of B-Raf by ATP-competitive inhibitors and can aid in the design of more potent and selective inhibitors without agonistic function.

Knowledge Graph

Similar Paper

Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors
Journal of Medicinal Chemistry 2015.0
Conformation-Specific Effects of Raf Kinase Inhibitors
Journal of Medicinal Chemistry 2012.0
Current Insights of BRAF Inhibitors in Cancer
Journal of Medicinal Chemistry 2018.0
Design, synthesis, and biological evaluation of new B-RafV600E kinase inhibitors
Bioorganic & Medicinal Chemistry 2018.0
Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors
Bioorganic & Medicinal Chemistry Letters 2011.0
Development of Novel, Highly Potent Inhibitors of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF): Increasing Cellular Potency through Optimization of a Distal Heteroaromatic Group
Journal of Medicinal Chemistry 2010.0
Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib
Journal of Medicinal Chemistry 2014.0
N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers
Journal of Medicinal Chemistry 2018.0
Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring
Journal of Medicinal Chemistry 2009.0
Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors
Bioorganic & Medicinal Chemistry 2010.0